Abbott settles TriCor antitrust claims for $22.5M

Twenty-three states reached a $22.5 million settlement against Abbott Laboratories and Fournier for blocking a cheaper substitute for the cholesterol-fighting drug TriCor. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.